Key result
Drosophila KCNQ channels display electrophysiological and pharmacological properties intermediate between mammalian neuronal and cardiac KCNQ channels, and can be sensitized to retigabine via a single amino acid substitution (M217W).
Drosophila KCNQ channels exhibit evolutionarily conserved electrophysiological and pharmacological properties with mammalian KCNQ channels, establishing Drosophila as a viable model for studying KCNQ channelopathies.
Establishes Drosophila as a tractable model for KCNQ channelopathies; extends conservation data but should not yet guide human therapies.
Of the five human KCNQ (Kv7) channels, KCNQ1 with auxiliary subunit KCNE1 mediates the native cardiac I(Ks) current with mutations causing short and long QT cardiac arrhythmias. KCNQ4 mutations cause deafness. KCNQ2/3 channels form the native M-current controlling excitability of most neurons, with mutations causing benign neonatal febrile convulsions. Drosophila contains a single KCNQ (dKCNQ) that appears to serve alone the functions of all the duplicated mammalian neuronal and cardiac KCNQ channels sharing roughly 50-60% amino acid identity therefore offering a route to investigate these channels. Current information about the functional properties of dKCNQ is lacking therefore we have investigated these properties here. Using whole cell patch clamp electrophysiology we compare the biophysical and pharmacological properties of dKCNQ with the mammalian neuronal and cardiac KCNQ channels expressed in HEK cells. We show that Drosophila KCNQ (dKCNQ) is a slowly activating and slowly-deactivating K(+) current open at sub-threshold potentials that has similar properties to neuronal KCNQ2/3 with some features of the cardiac KCNQ1/KCNE1 accompanied by conserved sensitivity to a number of clinically relevant KCNQ blockers (chromanol 293B, XE991, linopirdine) and opener (zinc pyrithione). We also investigate the molecular basis of the differential selectivity of KCNQ channels to the opener retigabine and show a single amino acid substitution (M217W) can confer sensitivity to dKCNQ. We show dKCNQ has similar electrophysiological and pharmacological properties as the mammalian KCNQ channels, allowing future study of physiological and pathological roles of KCNQ in Drosophila and whole organism screening for new modulators of KCNQ channelopathies.
No takes yet. Share an insight, caveat, or question.
Cavaliere et al. (2011) studied this question. Pharmacological KCNQ modulators (retigabine, zinc pyrithione, chromanol 293B, XE991, linopirdine) vs. Control (baseline/vehicle) was evaluated on Electrophysiological properties and pharmacological sensitivity (current amplitude and voltage activation). Drosophila KCNQ channels display electrophysiological and pharmacological properties intermediate between mammalian neuronal and cardiac KCNQ channels, and can be sensitized to retigabine via a single amino acid substitution (M217W).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: